ArticleJournal of thrombosis and haemostasis : JTH2019
Trauma-targeted delivery of tranexamic acid improves hemostasis and survival in rat liver hemorrhage model.
Article in Journal of thrombosis and haemostasis : JTH, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 34 citations in OpenAlex.
- Prehospital Lyophilized Plasma Transfusion for Trauma-Induced Coagulopathy in Patients at Risk for Hemorrhagic Shock: A Randomized Clinical Trial.JAMA network open · 2022Trial
- Recent advances in medical hemostatic materials: Mechanisms, evaluation, and clinical perspectives.iScience · 2026Review
- Development of ready-to-use tranexamic acid gauze as a hemostatic material for oral surgery: fabrication, hemostasis, and shelf-life.BMC oral health · 2026Article
- The effects of recombinant human activated factor VII and tranexamic acid on traumatic bleeding and mortality in mice.Research and practice in thrombosis and haemostasis · 2026Article
- Local delivery of tranexamic acid for hemorrhage control in trauma: a narrative review.Frontiers in drug delivery · 2026Review
- Biosynthetic blood surrogates: Current status and future opportunities.Bioengineering & translational medicine · 2025Review
- Contrast-Enhanced Ultrasound-Guided Microwave Ablation for Iatrogenic Hepatic Hemorrhage: A Feasibility Study on Precision Hemostasis.Bioengineering (Basel, Switzerland) · 2025Article
- Cargo-free particles divert neutrophil-platelet aggregates to reduce thromboinflammation.Nature communications · 2023Article
- Direct delivery of plasmin using clot-anchoring thrombin-responsive nanoparticles for targeted fibrinolytic therapy.Journal of thrombosis and haemostasis : JTH · 2023Article
- Review
- Platelet-inspired nanomedicine in hemostasis thrombosis and thromboinflammation.Journal of thrombosis and haemostasis : JTH · 2022Review
- Platelet-mimicking procoagulant nanoparticles augment hemostasis in animal models of bleeding.Science translational medicine · 2022Article
- Bioinspired artificial platelets: past, present and future.Platelets · 2022Review
- A Narrative Review of Different Hemostatic Materials in Emergency Treatment of Trauma.Emergency medicine international · 2022Review
- Recent advances in biopolymer-based hemostatic materials.Regenerative biomaterials · 2022Review
- On the Quest for In Vitro Platelet Production by Re-Tailoring the Concepts of Megakaryocyte Differentiation.Medicina (Kaunas, Lithuania) · 2020Review
- Hemostatic agents for prehospital hemorrhage control: a narrative review.Military Medical Research · 2020Review
- Bioinspired artificial platelets for transfusion applications in traumatic hemorrhage.Transfusion · 2020Review
- New considerations on pathways involved in acute traumatic coagulopathy: the thrombin generation paradox.World journal of emergency surgery : WJES · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
backgroundTrauma-associated hemorrhage and coagulopathy remain leading causes of mortality. Such coagulopathy often leads to a hyperfibrinolytic phenotype where hemostatic clots become unstable because of upregulated tissue plasminogen activator (tPA) activity. Tranexamic acid (TXA), a synthetic inhibitor of tPA, has emerged as a promising drug to mitigate fibrinolysis. TXA is US Food and Drug Administration-approved for treating heavy menstrual and postpartum bleeding, and has shown promise in trauma treatment. However, emerging reports also implicate TXA for off-target systemic coagulopathy, thromboembolic complications, and neuropathy.
objectiveWe hypothesized that targeted delivery of TXA to traumatic injury site can enable its clot-stabilizing action site-selectively, to improve hemostasis and survival while avoiding off-target effects. To test this, we used liposomes as a model delivery vehicle, decorated their surface with a fibrinogen-mimetic peptide for anchorage to active platelets within trauma-associated clots, and encapsulated TXA within them.
methodsThe TXA-loaded trauma-targeted nanovesicles (T-tNVs) were evaluated in vitro in rat blood, and then in vivo in a liver trauma model in rats. TXA-loaded control (untargeted) nanovesicles (TNVs), free TXA, or saline were studied as comparison groups.
resultsOur studies show that in vitro, the T-tNVs could resist lysis in tPA-spiked rat blood. In vivo, T-tNVs maintained systemic safety, significantly reduced blood loss and improved survival in the rat liver hemorrhage model. Postmortem evaluation of excised tissue from euthanized rats confirmed systemic safety and trauma-targeted activity of the T-tNVs.
conclusionOverall, the studies establish the potential of targeted TXA delivery for safe injury site-selective enhancement and stabilization of hemostatic clots to improve survival in trauma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.